Key facts
- It has raised $46.3M across 1 recorded rounds; the latest was Later Stage VC (Series A) ($40.1M) in Nov 2024.
- Notable investors include Y Combinator, Impact Assets, RA Capital Management, GV, Rebel Fund — 28 tracked in total.
- Synapticure has filed 1 Form D with the SEC, most recently Sep 2024 ($40.1M sold to 51 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Synapticure
Funding rounds
1 roundsAbout Synapticure
Developer of a virtual clinical care platform designed to identify and treat each patient's disease. The company's platform is based on advances in science, technology, and computational analytics to make sure that employees feel assisted in home working environment with the equipment they need to be successful with fully insured medical, dental, vision, and life insurance plans, enabling patients to get easy access to neurologists, behavioral health including psychiatry and therapy care coordination under one integrated care.
- Industry
- Clinics/Outpatient Services
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2019
- Employees
- 85
- Website
- synapticure.com/
- Ownership
- Privately Held (backing)
Synapticure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synapticure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synapticure in its N-PORT filings yet. We sweep new filings monthly.